Global Pain Management Devices Market Size & Trends Report Segmented by Product (Neurostimulator Devices, Infusion Pumps, Ablation Devices), Application (Cancer, Neuropathy, Trauma), End-User (Hospitals, Physiotherapy Clinics, Home-care Settings) & Regional Forecast to 2030

Overview

Pain management devices are specially designed medical equipment which aid in alleviating pain without the consumption of drugs like opioids. These devices either stimulate the body's natural pain reliever or block the transmission of pain signals from reaching the brain. Pain management devices are used to manage musculoskeletal disorders, neuropathic pain, cancer pain, and other chronic pain conditions. Neurostimulation devices, infusion pumps, electrical stimulators like TENS, and ablation devices are popular innovative devices in the market that assist in precise and personalized therapy. This personalized treatment approach eliminates the need for frequent clinical visits and offers the convenience of at-home care to the patients. Traditional opioid-based treatments have a risk of addiction and long-term inefficacy, so these devices are considered a safer and better pain relief alternative. Furthermore, integration with AI, advancements in closed-loop systems, and the development of point-of-care devices are expanding the market growth.

To learn more about this report, download the PDF brochure

Increasing burden of chronic conditions fuels demand

With the increasing adoption of a sedentary lifestyle across all age groups, there is surge in the chronic pain-inducing diseases like obesity, diabetes, arthritis, musculoskeletal, neurological disorders, etc.  According to the National Centre for Complementary and Integrative Health (NCCIH), 20.4% of US adults suffer from chronic pain. These chronic diseases have become common in the geriatric population. The World Health Organization (WHO) reports that chronic conditions like osteoarthritis have affected 528 million people globally. Additionally, on a global scale, osteoarthritis is the seventh leading cause of disability for individuals over the age of 70. Hence, with the rise in the number of people suffering from chronic pain, pain management devices are considered a better and effective alternative to drug-based treatment in the long run. Additionally, they offer minimal or non-invasive therapy, which eliminates the need for surgical procedures and is effective in long-term relief.

“Chronic pain is a dynamic, biopsychosocial human condition unique to each individual. To effectively treat suffering, as perceived by each patient, therapies must be personalized based on the changing experience of pain,”

• Chief Medical Officer, Leading MedTech Company US

Advent of advanced pain management technologies drives the pain management devices market

Currently, the first line of treatment for pain management is oral medication. Pain specialists/doctors prefer to prescribe medications over devices to patients majorly due to their easy availability, presence of substantial clinical evidence and lower cost. However, in recent years, the quality of treatment and care has improved immensely due to the development of advanced technologies. There are various types of pain management devices available in the market such as spinal cord stimulators, transcutaneous electrical nerve stimulation devices, etc. which help to block or mask entry of pain signals travelling to the brain. Recently, many developments have been made to improve the quality of life of patients suffering from chronic pain and also to reduce the effects of pain such as:

• In March 2025, AposHealth launched Apos® System, a non-invasive, foot-worn medical device designed to improve patients' gait cycle, thereby reducing chronic knee pain, offering a drug-free, biomechanical approach to long-term pain relief caused due to osteoarthritis
• In September 2024, Nevro launched HFX AdaptivAI, the first FDA-cleared AI-driven spinal cord stimulation (SCS) system, which utilize real-time data from patients' feedback to personalize therapy and improve pain relief
• In January 2024, Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval of its Percept RC Deep Brain Stimulation (DBS) system, a rechargeable neurostimulator and the latest innovation in the Percept family, which includes the Percept PC neurostimulator, BrainSense technology, and SenSight directional leads, making it the only sensing-enabled DBS system on the market that allows personalized treatment for movement disorders and epilepsy.
• In March 2023, Nevro Corp. announced the full U.S. market launch of its HFX iQ™ spinal cord stimulation (SCS) system, the first and only SCS system that uses artificial intelligence to personalize and maintain pain relief based on each patient's response

Shift to non-opioid-based treatment

Generally, opioids are prescribed to patients for managing chronic pain, but their long-term use can lead to dependence on these drugs and a high risk of addiction. According to an article published by the CDC, in 2022, approximately 108,000 people died in the US from drug overdoses, with 82,000 (76%) of those deaths involving opioids, representing a 10x increase in this number since 1999. Authorities like the FDA and the CDC, along with healthcare providers, are promoting the use of pain management devices because of their safety profile.  Pain management devices are considered a safe and effective alternative to opioid-based treatment because they reduce the risk of misuse and harmful side effects associated with opioid-based treatment. Devices like Spinal cord stimulators (SCS) and Transcutaneous electrical nerve stimulation (TENS) units help treat several chronic conditions like osteoarthritis and diabetic neuropathy. For instance,

• In September 2024, Zynex Inc. received FDA clearance for TensWave, a portable, non-invasive device designed for both acute and chronic pain management, which is also a safe, effective, and drug-free alternative to pain management
• In October 2023, Boston Scientific secured FDA approval to expand the application of the WaveWriter Alpha spinal cord stimulator to painful diabetic peripheral neuropathy, which is a better alternative than traditional treatment using medications

To learn more about this report, download the PDF brochure

Advancement in closed-loop neuromodulation systems

Closed-loop neuromodulation systems automatically adjust the stimulus intensity by interpreting real-time spinal cord activity. These devices use a patient-specific approach that ensures convenience and precision in therapy.  Unlike traditional open-loop systems, which have pre-determined responses, these devices provide personalized therapy. Additionally, integration of biomarker tracking and AI algorithms provides pain modulation in various chronic conditions, thereby ensuring optimal pain control and reduced overstimulation. For instance,

• In April 2024, Medtronic received FDA clearance for Inceptiv, which is the company's first closed-loop rechargeable spinal cord stimulator (SCS), which is capable of sensing 50 spinal cord signals per second, and it modulates the stimulation accordingly. Additionally, it is MRI-compatible, rechargeable, and can be integrated with a smart app called CareGuidePro for remote monitoring
• In April 2023, the FDA approved Biotronik’s Prospera Spinal Cord Stimulation (SCS) System, an implantable medical device that allows remote control with automatic and daily monitoring of stimulations, which mainly focuses on trunk and limb pain management

North America leads in terms of adoption of pain management devices

North America holds the largest market for pain management devices, followed by Europe and Asia Pacific. The growing prevalence of chronic pain conditions, demand for drug-free therapy, availability of well-planned reimbursement and insurance coverage and presence of leading players in this region are some of the key factors driving the market growth. Developed countries in Europe such as Germany, the UK and France are expected to grow significantly over the forecast period due to adopting the latest technology, new product launches and increased awareness regarding pain management devices. Asia Pacific region is expected to witness the highest CAGR in the coming years as manufacturers are expanding their foothold in the emerging Asia-Pacific countries due to a large patient base.

“New delivery models are emerging to address growing chronic care demands. Technology has a key role to play. Advancements in precise detection and diagnosis of diseases will go far to minimize the cost of treating chronic conditions.”  

• Executive Vice President, Global Operations and Supply Chain, Pain Management Device Company, Germany

Competitive Landscape Analysis

The global pain management devices market is marked by the presence of established and emerging market players such as Baxter International; Boston Scientific Corporation; Nevro Corp.; Abbott; Stryker Corporation; Medtronic plc; B Braun Melsungen AG; Omron Corporation; ICU Medical Inc; and Avanos Medical, among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Global Pain Management Devices Market Segmentation

This report by Medi-Tech Insights provides the size of the global pain management devices market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, and end-user.

Market Size & Forecast (2023-2030), By Product, USD Million

• • Neurostimulator Devices
  • Infusion Pumps
  • Ablation Devices
  • Electric Stimulators

Market Size & Forecast (2023-2030), By Application, USD Million

• • Cancer
  • Musculoskeletal Disorders
  • Neuropathy
  • Trauma
  • Others

Market Size & Forecast (2023-2030), By End-user, USD Million

• • Hospitals
  • Physiotherapy Clinics
  • Home-care Settings
  • Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Key Strategic Questions Addressed

• What is the market size & forecast of the pain management devices market?
• What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the pain management devices market?
• What are the key trends defining the market?
• What are the major factors impacting the market?
• What are the opportunities prevailing in the market?
• Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
• Who are the major players operating in the market?
• What are the key strategies adopted by players?